Eli Lilly Accelerates Baricitinib Availability in India Amid Covid-19 Surge
By Colin Kellaher
Eli Lilly & Co. on Tuesday said it is donating hundreds of
thousands of doses of baricitinib to the Indian government, as the
nation of more than 1.3 billion people grapples with a massive
The Indianapolis drug maker said India's government approved
restricted emergency use of the drug, which the company markets as
Olumiant for the treatment of rheumatoid arthritis, as a Covid-19
therapy via donations and licensing agreements.
The company said it is making an initial donation of 400,000
baricitinib tablets immediately available to the Indian government
for eligible hospitalized Covid-19 patients, adding that it is
working with Indian pharmaceutical companies to execute
royalty-free voluntary licensing agreements to speed production and
distribution of drug during the pandemic.
Eli Lilly said the emergency authorization covers the use of
baricitinib in hospitalized Covid-19 patients who need supplemental
oxygen, invasive mechanical ventilation or extracorporeal membrane
The U.S. Food and Drug Administration in November authorized the
emergency use of baricitinib in combination with Gilead Sciences
Inc.'s remdesivir for Covid-19 patients needing supplemental oxygen
or on a mechanical ventilator.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
May 04, 2021 08:17 ET (12:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.